Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026)

Neumora Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $88.0 million (up 345.21% YoY), while the FY2025 annual figure was $77.1 million, up 256.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $10.9 million, down from $58.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $232.0 million in Q3 2023, with the low at -$481000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $2.7 million (2024), against an average of $28.3 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 3337.63% in 2024, then plunged 108.88% in 2025.
• Neumora Therapeutics' Cash from Financing Activities stood at $26.8 million in 2022, then slumped by 101.79% to -$481000.0 in 2023, then soared by 3337.63% to $15.6 million in 2024, then surged by 277.37% to $58.8 million in 2025, then sank by 81.5% to $10.9 million in 2026.
• Business Quant data shows NMRA's Cash from Financing Activities at $10.9 million in Q1 2026, $58.8 million in Q4 2025, and -$136000.0 in Q3 2025.